Promoter shareholding stable; institutions increased by 1.14% YoY, outperforming sector average which remained unchanged.
Public shareholding slightly decreased, indicating limited retail interest; however, strong institutional support suggests confidence in Ajanta Pharma's future.
In a sector with mixed performances, Ajanta's institutional growth stands out positively against peers like SANOFICONR (20.63% increase) and NECTAR LIFE (-15.93% decrease).